<DOC>
	<DOCNO>NCT02182895</DOCNO>
	<brief_summary>The purpose research study test safety efficacy drug call saxagliptin ( Onglyza ) treatment type 2 diabetes non-critically ill hospitalize patient HbA1c 7.5 low , 1 non-insulin agent home , HbA1c ≤7.0 % ≤ 2 non-insulin agent home .</brief_summary>
	<brief_title>Safety Efficacy Saxagliptin Glycemic Control Non-Critically Ill Hospitalized Patient</brief_title>
	<detailed_description>The current professional organization guideline recommend insulin preferred treatment hospitalize patient . It recommend critically ill patient receive insulin infusion therapy non-critically ill patient receive basal bolus insulin therapy hospital . The study test hypothesis treatment saxagliptin non-inferior treatment basal bolus insulin group patient hospital stay . The study evaluate effect saxagliptin , DPP4 inhibitor , glycemic control non-critically ill hospitalize patient type 2 diabetes mellitus ( T2DM ) The primary outcome mean daily blood glucose level hospital day 2 5 . The study design detect non-inferiority margin 20 % saxagliptin group compare control group</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Saxagliptin</mesh_term>
	<mesh_term>Dipeptidyl-Peptidase IV Inhibitors</mesh_term>
	<criteria>Patients T2DM HbA1C ≤7.5 % ≤1 noninsulin hypoglycemic agent HbA1C ≤7.0 % ≤2 noninsulin hypoglycemic agent admit hospital noncritical illness . Written informed consent . Admitted expected require admission ICU Patients history diabetic ketoacidosis hyperosmolar state HbA1c &gt; 7.5 % time admission within 3 month admission Insulin require admission Unable take oral food medication Systemic steroid use Pregnancy breastfeed Women ChildBearing Potential ( WOCBP ) unwilling unable use acceptable method avoid pregnancy entire study period 4 week last dose study drug . History pancreatitis active gallbladder disease End stage renal disease dialysis Hypersensitivity saxagliptin another contraindication DPP4 inhibitor Subject unable give inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>110 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>